Clinical Trials
385 trialsBELINDA
Novartis
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Dizal Pharmaceuticals
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
RELATIVITY-069
Bristol-Myers Squibb
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
MK-4280-003
Merck Sharp & Dohme LLC
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
A Study of LP-118 in Patients With Advanced Tumors
Guangzhou Lupeng Pharmaceutical Company LTD.
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
TRuST
Ipsen
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
CHRONOS-3
Bayer
ELM-1
Regeneron Pharmaceuticals
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
ARC-12
Arcus Biosciences, Inc.
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Janssen Research & Development, LLC
TRANSFORM
Celgene
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
SYMPATICO
Pharmacyclics LLC.
MAGNIFY
Celgene
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
Celgene
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Celgene
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Otsuka Beijing Research Institute
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
(CITADEL-205)
Incyte Corporation
CITADEL-203
Incyte Corporation
Meteor 1
GlaxoSmithKline
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
Dizal Pharmaceuticals
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Denovo Biopharma LLC
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
TRANSCENDWORLD
Celgene
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
ROOT
Taproot Health
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Kymera Therapeutics, Inc.
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
MB-CART20.1 Lymphoma
Miltenyi Biomedicine GmbH
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
Pfizer